

## Prestige BioPharma Group Completes its Campus 1 Annex in Osong South Korea



[Front view of Campus 1 Annex (left), Completion Ceremony of Campus 1 Annex (right)]

**[29 October 2021]** / Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, is pleased to announce the completion of PBP Group’s Campus 1 Annex in Osong, South Korea.

PBP Group commenced construction of its Osong Campus 1 Annex in May this year and completed the multi-purpose building with a total area of 10,014m<sup>2</sup> in only six months by using Prestige Biologics’ proprietary engineering technology, ALITA Smart BioFactory™. PBP’s commercial vaccine production unit in the Campus 1 Annex is currently under validation and PBP Group’s R&D and other manufacturing facility will be installed in this building as well.

PBP began the process of pilot production of Sputnik V COVID19 vaccine in last August and the newly installed vaccine unit in the Campus 1 Annex is for commercial production.

Apart from this, PBP’s main vaccine centre with a total area of 10,342m<sup>2</sup> is being built in Osong Campus 2 site and it is on target to complete the construction by the end of this year.

PBP’s CEO, Dr Lisa S. Park commented, “the Campus 1 Annex has been completed and the Campus 2’s vaccine centre and antibody drug manufacturing facility are on the verge of completion as planned earlier this year” and “we will complete a production system validation and procure necessary equipment to establish a reliable manufacturing facility for vaccine and antibody drug”.